Cerulean (NASDAQ:CERU) reported first quarter results and provided a pipeline update on May 2, while confirming an expected cash runway for the company into 2017.
Management has pushed back its timing for an announcement on the highly awaited top-line data for CRLX101 in renal cancer. Critical Phase II top-line data in RCC are now expected in Q316 (changed from end-June), due to an apparent slowing of the rate of disease progression in patients.
Phase II top-line data in renal now in Q316
Cerulean will now report highly awaited top-line data (progression-free survival and overall response rates) from its Phase II trial of CRLX101 with Avastin in advanced renal cell carcinoma (mRCC) in Q316.
Up until a few weeks ago, results were expected by the end of June, with management reporting the change on an apparent recent slowdown in the rate of disease progression. Positive results would lead to the initiation of a Phase III study in mRCC by year end.
Meanwhile, upcoming news in Q216 includes the dosing of first patients in a Phase Ib/II trial for the Cerulean-AZ-NCI collaboration and the initiation of a Phase IIa trial of CRLX301 in solid tumors.
To read the entire report, please click on the PDF file below.